The homepage sketched out three points: the crystal edge, the exchangeable reservoir, and a second site on an enzyme active in bone turnover. This Orientation goes through each of them individually, adds a distribution table, and lays out the complete text of the regulation.
Hydroxyapatite doesn’t form as a finished product — it keeps building up at its surface while material is broken down elsewhere at the same time. It’s exactly at this developing surface that other, smaller ions settle in alongside calcium and phosphate — magnesium among them.
Unlike calcium, magnesium is rarely taken up deep into the ordered crystal lattice. It stays mostly at the outer surface, where, in small amounts, it disrupts the orderly attachment of further ions. Research on crystal formation describes this disruptive effect as one factor that influences how large and how mature individual crystal grains become before they shift into a more stable form.
This near-surface contact is one of the two points the scientific background behind the following claim rests on:
More magnesium sits in the skeleton than in any other single tissue in the body — part of it locked into the crystal lattice, another part only loosely bound at the crystal surface. These two fractions behave differently: the near-surface share stays in constant exchange with the surrounding tissue, while the deeply embedded share largely stays put unless the crystal itself is rebuilt.
The readily available share acts like a buffer: if the blood concentration dips briefly, a small part of the surface-bound magnesium can be released without the whole bone needing to be rebuilt for it. The more deeply embedded share, by contrast, follows the slower pace of bone renewal itself.
Bone is renewed in small sections throughout life: osteoclasts break down older material, and osteoblasts lay down new crystal material in the same spot. With every one of these cycles, the magnesium bound within it is also released or rebuilt into place. Research also describes how the activity of these two cell types tends to track the magnesium available in the surrounding tissue — a connection that counts as background knowledge for the claim cited above, not as a separate part of its wording.
Alkaline phosphatase is among the enzymes involved in bone turnover: it splits pyrophosphate, a molecule that would otherwise slow crystal formation, while at the same time freeing up phosphate for new material. The enzyme is best known as a zinc-dependent metalloenzyme — its catalytic centers carry zinc ions.
Alongside that, the biochemical literature describes a second binding site, separate from the catalytic centers, where magnesium ions dock and help set the enzyme’s activity level. This second site isn’t a substitute for the zinc centers — it’s a distinct, additional spot on the same protein.
Calcium and phosphate are part of this picture too — but only as building blocks of the crystal lattice itself, not as a claim of their own on this page. Both have their own separately reviewed EU claims, which this Orientation doesn’t go into further.
A rough breakdown based on physiological literature, not a lab result for any one individual.
| Fraction or Source | Context |
|---|---|
| Near the crystal surface | quickly exchangeable, short-term buffer |
| Deep in the crystal lattice | firmly embedded, follows the pace of bone renewal |
| Muscle and soft tissue | second-largest share of the body’s total |
| Blood serum | very small share, held within a narrow range |
| Cocoa and dark chocolate | comparatively high content per 100 g |
| Oats and other whole-grain products | meaningful content per 100 g |
Food values shift with growing conditions, variety, and preparation; the table is meant as a general guide, not for calculating an exact daily amount.
Crystal edge, reservoir, and the second enzyme site explain why researchers took an interest in magnesium in connection with bone. Legally authorized and to be quoted unchanged, though, is exclusively this sentence:
No. The wording refers to nothing more than the ordinary physiological process, assuming a magnesium intake that overall meets requirements; it makes no mention of any increase or speeding-up beyond that.
No. It doesn’t single out a particular age group; it addresses adults in general.
No. The crystal surface, the reservoir, and the enzyme site are scientific background from the literature that places the claim in context. The reviewed wording itself records only the short, overall finding.
No. Calcium and phosphorus each have their own, separately reviewed EU claims. This Orientation quotes only the claim on magnesium.
No. What’s here is organized knowledge drawn from openly available scientific sources. Anyone who needs an examination or personal advice should turn to a doctor or pharmacist.
All four sections of this page, the distribution table, and the complete text of the regulation stay available to revisit anytime after purchase.
$49.00
One-time access · Digital information product
A dietary supplement doesn’t replace a varied diet or a generally balanced daily routine. Stay within the daily amount given on the package, and put the product somewhere kids can’t get to it. Anyone taking medication regularly or with a known kidney condition should discuss additional magnesium intake with a doctor or pharmacist beforehand. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
If you found Wollastoniteon through an ad on Google or in front of a YouTube video, here’s what that means: it’s a paid ad placement, nothing more. Google LLC, YouTube LLC, and their parent company Alphabet Inc. have no involvement in this site and did not write, review, or endorse the text beforehand. Google and YouTube are trademarks owned by Google LLC.
There’s also a plain mailbox for this page, no form attached: [email protected]